These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 16475959)

  • 21. Serotonergic modulation of the activity of mesencephalic dopaminergic systems: Therapeutic implications.
    De Deurwaerdère P; Di Giovanni G
    Prog Neurobiol; 2017 Apr; 151():175-236. PubMed ID: 27013075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biochemical and electrophysiological evidence that RO 60-0175 inhibits mesolimbic dopaminergic function through serotonin(2C) receptors.
    Di Matteo V; Di Giovanni G; Di Mascio M; Esposito E
    Brain Res; 2000 May; 865(1):85-90. PubMed ID: 10814735
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Involvement of dopamine (DA)/serotonin (5-HT)/sigma (sigma) receptor modulation in mediating the antidepressant action of ropinirole hydrochloride, a D2/D3 dopamine receptor agonist.
    Dhir A; Kulkarni SK
    Brain Res Bull; 2007 Sep; 74(1-3):58-65. PubMed ID: 17683790
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Mechanism of action of antidepressants and therapeutic perspectives].
    Bourin M; David DJ; Jolliet P; Gardier A
    Therapie; 2002; 57(4):385-96. PubMed ID: 12422559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serotonin receptors: their key role in drugs to treat schizophrenia.
    Meltzer HY; Li Z; Kaneda Y; Ichikawa J
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1159-72. PubMed ID: 14642974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors.
    Guiard BP; El Mansari M; Blier P
    Curr Drug Targets; 2009 Nov; 10(11):1069-84. PubMed ID: 19702555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of dopamine release by striatal 5-HT2C receptors.
    Alex KD; Yavanian GJ; McFarlane HG; Pluto CP; Pehek EA
    Synapse; 2005 Mar; 55(4):242-51. PubMed ID: 15668911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5-HT2 receptor blockade by ICI 169,369 and other 5-HT2 antagonists modulates the effects of D-2 dopamine receptor blockade.
    Saller CF; Czupryna MJ; Salama AI
    J Pharmacol Exp Ther; 1990 Jun; 253(3):1162-70. PubMed ID: 2141636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The importance of brain serotonergic receptor mechanisms for the action of antidepressant drugs.
    Ogren SO; Fuxe K; Agnati L
    Pharmacopsychiatry; 1985 Mar; 18(2):209-13. PubMed ID: 3927330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Brain noradrenaline and the mechanisms of action of antidepressant drugs.
    Svensson TH
    Acta Psychiatr Scand Suppl; 2000; 402():18-27. PubMed ID: 10901155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Endocrine and receptor pharmacology of serotonergic anxiolytics, antipsychotics and antidepressants.
    Levy AD; Van de Kar LD
    Life Sci; 1992; 51(2):83-94. PubMed ID: 1352027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serotonin(2C) receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a combined dialysis and electrophysiological analysis in the rat.
    Gobert A; Rivet JM; Lejeune F; Newman-Tancredi A; Adhumeau-Auclair A; Nicolas JP; Cistarelli L; Melon C; Millan MJ
    Synapse; 2000 Jun; 36(3):205-21. PubMed ID: 10819900
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serotonin receptors involved in antidepressant effects.
    Artigas F
    Pharmacol Ther; 2013 Jan; 137(1):119-31. PubMed ID: 23022360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. On the mechanism of antidepressant-like action of berberine chloride.
    Kulkarni SK; Dhir A
    Eur J Pharmacol; 2008 Jul; 589(1-3):163-72. PubMed ID: 18585703
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of serotonin in central dopamine dysfunction.
    Di Giovanni G; Esposito E; Di Matteo V
    CNS Neurosci Ther; 2010 Jun; 16(3):179-94. PubMed ID: 20557570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectivity in the mesolimbic dopaminergic system.
    Andersson JL; Nomikos GG; Marcus M; Hertel P; Mathé JM; Svensson TH
    Naunyn Schmiedebergs Arch Pharmacol; 1995 Oct; 352(4):374-85. PubMed ID: 8532065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atorvastatin evokes a serotonergic system-dependent antidepressant-like effect in mice.
    Ludka FK; Constantino LC; Kuminek G; Binder LB; Zomkowski AD; Cunha MP; Dal-Cim T; Rodrigues AL; Tasca CI
    Pharmacol Biochem Behav; 2014 Jul; 122():253-60. PubMed ID: 24769309
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A short history of the 5-HT
    Palacios JM; Pazos A; Hoyer D
    Psychopharmacology (Berl); 2017 May; 234(9-10):1395-1418. PubMed ID: 28265714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stimulation of glutamate receptors in the ventral tegmental area is necessary for serotonin-2 receptor-induced increases in mesocortical dopamine release.
    Pehek EA; Hernan AE
    Neuroscience; 2015 Apr; 290():159-64. PubMed ID: 25637799
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Galanin receptor antagonists : a potential novel pharmacological treatment for mood disorders.
    Ogren SO; Kuteeva E; Hökfelt T; Kehr J
    CNS Drugs; 2006; 20(8):633-54. PubMed ID: 16863269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.